# Axil Brands, Inc.: overview AXIL · NYSE · CIK 1718500 · [Consumer staples](/sectors/consumer-staples.md) · fiscal year ends May 31 Pages: [Overview](/companies/axil.md) · [Financials](/companies/axil/financials.md) · [Filings](/companies/axil/filings.md) · [Insiders](/companies/axil/insiders.md) Latest reported revenue: [$6.1m](/filings/0001520138-26-000410.md) for Q1 FY2027, three months to 2026-08-31, from the 10-Q filed Oct 6, 2026 (XBRL us-gaap:Revenues, accession 0001520138-26-000410). ## Last eight quarters | Line item | Unit | Q2 FY2025 (2024-11-30) | Q3 FY2025 (2025-02-28) | Q4 FY2025 (2025-05-31) | Q1 FY2026 (2025-08-31) | Q2 FY2026 (2025-11-30) | Q3 FY2026 (2026-02-28) | Q4 FY2026 (2026-05-31) | Q1 FY2027 (2026-08-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $k | [7,733](/filings/0001520138-26-000006.md) | [6,922](/filings/0001520138-26-000104.md) | [5,751 d](/filings/0001520138-26-000360.md) | [6,856](/filings/0001520138-26-000410.md) | [8,135](/filings/0001520138-26-000006.md) | [7,294](/filings/0001520138-26-000104.md) | [8,562 d](/filings/0001520138-26-000360.md) | [6,090](/filings/0001520138-26-000410.md) | | Gross margin | % | [71.1%](/filings/0001520138-26-000006.md) | [71.7%](/filings/0001520138-26-000104.md) | [70.0% d](/filings/0001520138-26-000360.md) | [67.6%](/filings/0001520138-26-000410.md) | [68.1%](/filings/0001520138-26-000006.md) | [69.1%](/filings/0001520138-26-000104.md) | [72.0% d](/filings/0001520138-26-000360.md) | [82.6%](/filings/0001520138-26-000410.md) | | Operating margin | % | [8.7%](/filings/0001520138-26-000006.md) | [8.4%](/filings/0001520138-26-000104.md) | [0.8% d](/filings/0001520138-26-000360.md) | [6.0%](/filings/0001520138-26-000410.md) | [11.1%](/filings/0001520138-26-000006.md) | [2.9%](/filings/0001520138-26-000104.md) | [16.9% d](/filings/0001520138-26-000360.md) | [7.2%](/filings/0001520138-26-000410.md) | | Net margin | % | [8.2%](/filings/0001520138-26-000006.md) | [8.3%](/filings/0001520138-26-000104.md) | [(4.3%) d](/filings/0001520138-26-000360.md) | [4.9%](/filings/0001520138-26-000410.md) | [8.7%](/filings/0001520138-26-000006.md) | [2.8%](/filings/0001520138-26-000104.md) | [17.0% d](/filings/0001520138-26-000360.md) | [6.9%](/filings/0001520138-26-000410.md) | | Diluted EPS | $ per share | [0.08](/filings/0001520138-26-000006.md) | [0.07](/filings/0001520138-26-000104.md) | not reported | [0.04](/filings/0001520138-26-000410.md) | [0.09](/filings/0001520138-26-000006.md) | [0.02](/filings/0001520138-26-000104.md) | not reported | [0.05](/filings/0001520138-26-000410.md) | | Free cash flow | $k | [941 d](/filings/0001520138-26-000006.md) | [(318) d](/filings/0001520138-26-000104.md) | [135 d](/filings/0001520138-26-000360.md) | [(748)](/filings/0001520138-26-000410.md) | [906 d](/filings/0001520138-26-000006.md) | [553 d](/filings/0001520138-26-000104.md) | [(801) d](/filings/0001520138-26-000360.md) | [3,707](/filings/0001520138-26-000410.md) | - Revenue. XBRL Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquireProductiveAssets; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 6-month figure less the 3-month figure; 9-month figure less the 6-month figure; 12-month figure less the 9-month figure. ## Last five fiscal years | Line item | Unit | FY2022 (2022-05-31) | FY2023 (2023-05-31) | FY2024 (2024-05-31) | FY2025 (2025-05-31) | FY2026 (2026-05-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [2.3](/filings/0001520138-23-000335.md) | [23.5](/filings/0001520138-24-000274.md) | [27.5](/filings/0001520138-25-000275.md) | [26.3](/filings/0001520138-26-000360.md) | [30.8](/filings/0001520138-26-000360.md) | | Gross margin | % | [64.5%](/filings/0001520138-23-000335.md) | [75.3%](/filings/0001520138-24-000274.md) | [73.4%](/filings/0001520138-25-000275.md) | [71.0%](/filings/0001520138-26-000360.md) | [69.3%](/filings/0001520138-26-000360.md) | | Operating margin | % | [(9.0%)](/filings/0001520138-23-000335.md) | [8.4%](/filings/0001520138-24-000274.md) | [5.5%](/filings/0001520138-25-000275.md) | [4.4%](/filings/0001520138-26-000360.md) | [9.7%](/filings/0001520138-26-000360.md) | | Net margin | % | [(7.8%)](/filings/0001520138-23-000335.md) | [7.8%](/filings/0001520138-24-000274.md) | [7.3%](/filings/0001520138-25-000275.md) | [3.3%](/filings/0001520138-26-000360.md) | [8.8%](/filings/0001520138-26-000360.md) | | Diluted EPS | $ per share | [0.00](/filings/0001520138-23-000335.md) | [0.10](/filings/0001520138-24-000274.md) | [0.21](/filings/0001520138-25-000275.md) | [0.10](/filings/0001520138-26-000360.md) | [0.33](/filings/0001520138-26-000360.md) | | Free cash flow | $m | not reported | [2.9](/filings/0001520138-24-000274.md) | [(0.1)](/filings/0001520138-25-000275.md) | [1.7](/filings/0001520138-26-000360.md) | [(0.1)](/filings/0001520138-26-000360.md) | - Revenue. XBRL Revenue: us-gaap:Revenues. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:Revenues. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/axil/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [Private Advisory Group LLC](/funds/1632965.md) | 2026-06-30 | $2.2m | 334,756 | | Unchanged | | [Soltis Investment Advisors LLC](/funds/1802530.md) | 2026-06-30 | $1.2m | 180,002 | | Unchanged | | [DIVERSIFY WEALTH MANAGEMENT, LLC](/funds/2030780.md) | 2026-06-30 | $986.0k | 164,331 | | Reduced −22,125 | | [Diversify Advisory Services, LLC](/funds/2021232.md) | 2026-06-30 | $986.0k | 164,331 | | New +164,331 | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $471.5k | 70,379 | | Added +10,687 | | [WELLS FARGO & COMPANY/MN](/funds/72971.md) | 2026-06-30 | $265.9k | 39,688 | | Unchanged | | [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $256.3k | 38,260 | | Unchanged | | [VANGUARD FIDUCIARY TRUST CO](/funds/933478.md) | 2026-06-30 | $132.5k | 19,781 | | Added +145 | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $91.2k | 13,605 | | Added +3,480 | | [CITADEL ADVISORS LLC](/funds/1423053.md) | 2026-06-30 | $87.4k | 13,039 | | New +13,039 | ## Recent filings [All 172 filings](/companies/axil/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-22 | 20:15 ET | [DEF 14A](/filings/0001520138-26-000433.md) | Proxy statement, period 2026-10-22 | 0001520138-26-000433 | | 2026-10-20 | 20:05 ET | [SCHEDULE 13D/A](/filings/0001520138-26-000425.md) | Ownership report, active investor, amended | 0001520138-26-000425 | | 2026-10-06 | 20:20 ET | [8-K](/filings/0001520138-26-000411.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001520138-26-000411 | | 2026-10-06 | 20:15 ET | [10-Q](/filings/0001520138-26-000410.md) | Quarterly report, period 2026-08-31 | 0001520138-26-000410 | | 2026-08-20 | 20:15 ET | [SCHEDULE 13D/A](/filings/0001520138-26-000368.md) | Ownership report, active investor, amended | 0001520138-26-000368 | | 2026-08-18 | 20:15 ET | [8-K](/filings/0001520138-26-000361.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001520138-26-000361 | | 2026-08-18 | 20:10 ET | [10-K](/filings/0001520138-26-000360.md) | Annual report, period 2026-05-31 | 0001520138-26-000360 | | 2026-04-08 | 12:05 ET | [8-K](/filings/0001520138-26-000105.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001520138-26-000105 | | 2026-04-08 | 12:00 ET | [10-Q](/filings/0001520138-26-000104.md) | Quarterly report, period 2026-02-28 | 0001520138-26-000104 | | 2026-01-20 | 21:16 ET | [8-K](/filings/0001520138-26-000032.md) | 5.02 Departure or appointment of officers or directors | 0001520138-26-000032 | ## Latest annual report [Form 10-K for the fiscal year ended May 31, 2026](/filings/0001520138-26-000360.md), filed Aug 18, 2026. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 1718500 - Tickers: AXIL - Exchange: NYSE - SIC code: 2844 Perfumes, Cosmetics & Other Toilet Preparations - State of incorporation: DE - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:46 ET. No prices; not investment advice.